Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (833 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from androstenedione directly, or from testosterone via estradiol. In humans, it is produced primarily by the cyclic ovaries, placenta, and the adipose tissue of men and postmenopausal women.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Estrone, (9 beta)-Isomer; Estrone, (+-)-Isomer; Estrone, (8 alpha)-Isomer; Folliculin (Hormone); Estrovarin; Kestrone; Unigen; Wehgen.
Where it fits in the MeSH classification
- Broader topics
- Estrenes; 17-Ketosteroids; Estradiol Congeners
- Narrower topics
- Hydroxyestrones
Related concepts
Research landscape
PubMed indexes 10,416 records tagged with the MeSH heading “Estrone” (counts retrieved 2026-10-31). 598 of them (5.7%) were published from 2020 onward, and the busiest period so far is through 1999 with 7,364 records.
Reviews account for 284 records (2.7%) and meta-analyses for 8. Randomized controlled trials number 281 (2.7%) as a share of all records on the topic.
Show the data
| Period | Records |
|---|---|
| through 1999 | 7,364 |
| 2000-2009 | 1,310 |
| 2010-2019 | 1,144 |
| 2020 onward | 598 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 284 | 2.7% |
| Meta-analyses | 8 | 0.1% |
| Randomized controlled trials | 281 | 2.7% |
Method: PubMed query "Estrone"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in drugs and chemicals
Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Sex-specific Estrogen Levels and Reference Intervals from Infancy to Late Adulthood Determined by LC-MS/MS | 2020 | Research article Design not recorded in structured metadata | 168 | cc by PMID 31720688 · DOI · PMC7007877 |
| Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up | 1998 | Research article Design not recorded in structured metadata | 109 | cc by PMID 9820189 · DOI · PMC2063014 |
| Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma | 2018 | Research article Design not recorded in structured metadata | 44 | cc by PMID 29644882 · DOI · PMC6058671 |
| Synthesis and Characterization of Chemically Stable N7-dG Estrone and Catechol Adducts | 2026 | Research article Design not recorded in structured metadata | 0 | cc by PMID 42197187 · DOI · PMC13209890 |
Sex-specific Estrogen Levels and Reference Intervals from Infancy to Late Adulthood Determined by LC-MS/MS [1]
Abstract reading summary — source excerpts
- Opening excerpt
- ContextThe lack of sensitive and robust analytical methods has hindered the reliable quantification of estrogen metabolites in subjects with low concentrations.
- Closing excerpt
- In girls, E2 levels ranged from ConclusionReference ranges of simultaneous quantification of E1 and E2 by this novel specific and highly sensitive LC-MS/MS method provide an invaluable tool in clinical practice and in future research studies.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (170 words)
ContextThe lack of sensitive and robust analytical methods has hindered the reliable quantification of estrogen metabolites in subjects with low concentrations.ObjectiveTo establish sex-specific reference ranges for estrone (E1) and estradiol (E2) throughout life and to evaluate sex-differences using the state-of-the-art liquid chromatography tandem mass spectrometry (LC-MS/MS) method for quantification of E1, E2, and estriol (E3).DesignLC-MS/MS method development and construction of estrogen reference ranges.SettingsPopulation-based cross-sectional cohorts from the greater Copenhagen and Aarhus areas.ParticipantsHealthy participants aged 3 months to 61 years (n = 1838).ResultsAn isotope diluted LC-MS/MS method was developed and validated for measurements of serum E1, E2, and E3. Limits of detections (LODs) were 3 pmol/L (E1), 4 pmol/L (E2), and 12 pmol/L (E3), respectively. This sensitive method made it possible to differentiate between male and female concentration levels of E1 and E2 in children. In girls, E2 levels ranged from ConclusionReference ranges of simultaneous quantification of E1 and E2 by this novel specific and highly sensitive LC-MS/MS method provide an invaluable tool in clinical practice and in future research studies.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31720688 · DOI · PMC7007877
Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up [2]
Abstract reading summary — source excerpts
- Opening excerpt
- This is the first prospective study of urinary measures of the two major competing pathways of oestrogen metabolism, 16alpha-hydroxyoestrone (16alpha-OHE1) and 2-hydroxyoestrone (2-OHE1), in relation to incident breast cancer risk.
- Closing excerpt
- It is of potential importance that, in contrast to most risk factors for breast cancer, such as late age at first birth, oestrogen metabolism appears to be modifiable via diet and exercise, offering women the possibility of lowering breast cancer risk through non-pharmacological measures, although this remains to be tested.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (242 words)
This is the first prospective study of urinary measures of the two major competing pathways of oestrogen metabolism, 16alpha-hydroxyoestrone (16alpha-OHE1) and 2-hydroxyoestrone (2-OHE1), in relation to incident breast cancer risk. Experimental and case-control study results suggest that metabolism favouring the more oestrogenic 16alpha-OHE1 pathway may be linked to higher breast cancer risk. Women aged 35 and older from Guernsey (n = 5104) were surveyed in 1977-85 and have been continuously monitored for breast cancer and mortality up to the present (Guernsey III, Imperial Cancer Research Fund). Incident cases of breast cancer were matched to three control subjects for comparison of urinary oestrogen metabolite levels measured by enzyme immunoassay (EIA) in spot urine samples collected at baseline and stored frozen for up to 19 years. Consistent with case-control study results, post-menopausal (but not premenopausal) women at baseline who went on to develop breast cancer showed about a 15% lower 2:16alpha-OHE1 ratio than matched control subjects. Further, subjects with metabolite ratios in the highest tertile of 2:16alpha-OHE1 had about a 30% lower risk than women with ratios in the lowest two-thirds, although results were not statistically significant (OR = 0.71, 95% CI = 0.29-1.75). It is of potential importance that, in contrast to most risk factors for breast cancer, such as late age at first birth, oestrogen metabolism appears to be modifiable via diet and exercise, offering women the possibility of lowering breast cancer risk through non-pharmacological measures, although this remains to be tested.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 9820189 · DOI · PMC2063014
Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma [3]
Abstract reading summary — source excerpts
- Opening excerpt
- An estrogen (ES)-functionalized cationic liposomal system was developed and exploited for targeted delivery to osteosarcoma.
- Closing excerpt
- Overall, the COS grafted estrogen-functionalized cationic liposomes, fortified with glutathione-responsiveness, showed great potential for specific intracellular drug delivery to estrogen receptor-expressing tumors such as osteosarcoma.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (226 words)
An estrogen (ES)-functionalized cationic liposomal system was developed and exploited for targeted delivery to osteosarcoma. Natural biocompatible chotooligosaccharides (COS, MW2-5 KDa) were covalently tethered to the liposomal surface through a disulfate bond (-SS-) to confer reduction-responsive COS detachment, whereas estrogen was grafted via polyethylene glycol (PEG 2 K) chain to achieve estrogen receptor-targeting. The liposomal carriers were prepared by the ethanol injection method and fluorescent anticancer drug doxorubicin (DOX) was loaded with ammonium sulfate gradient. The physicochemical properties, reduction-sensitivity, and the roles of estrogen on cellular uptake and tumor-targeting were studied. The Chol-SS-COS/ES/DOX liposomes were spherical with an average size about 110 nm, and high encapsulation efficiency. The liposomes were stable in physiological condition but rapidly release the payload in response to tumoral intracellular glutathione (20 mM). MTT cytotoxicity assay confirmed that Chol-SS-COS/ES/DOX liposomes exhibited higher cytotoxicity to MG63 osteosarcoma cells than to liver cells (LO2). Flow cytometry (FCM) and confocal laser scanning microscopy revealed that cellular uptake of Chol-SS-COS/ES/DOX liposomes by MG63, than the free DOX or Chol-SS-COS/DOX. Ex vivo fluorescence distribution study showed that the multifunctional liposomes selectively accumulated in the MG63 xenografts versus the organs. Chol-SS-COS/ES/DOX liposomes strongly inhibited the tumor growth and enhanced the animal survival rate. Overall, the COS grafted estrogen-functionalized cationic liposomes, fortified with glutathione-responsiveness, showed great potential for specific intracellular drug delivery to estrogen receptor-expressing tumors such as osteosarcoma.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29644882 · DOI · PMC6058671
Synthesis and Characterization of Chemically Stable N7-dG Estrone and Catechol Adducts [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Endogenous estrogens are implicated in carcinogenesis through both estrogen receptor-mediated cell proliferation and the direct genotoxicity of reactive metabolites.
- Closing excerpt
- These findings provide the first synthesized stable models of N7-dG estrogen adducts and may support an alternative mechanism of estrogen-induced mutagenesis independent of depurination, enabling future biochemical investigations of related DNA repair and mutagenesis.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (195 words)
Endogenous estrogens are implicated in carcinogenesis through both estrogen receptor-mediated cell proliferation and the direct genotoxicity of reactive metabolites. Oxidative metabolism of estrogens produces catechol estrogens that are further converted to electrophilic ortho-quinones capable of alkylating DNA. The prevailing model of mutagenesis proposes that these N3Ade and N7Gua adducts depurinate to form abasic sites that induce mutations initiating hormone-related cancers. However, the mutation spectrum observed in experimental data is inconsistent with this mechanism, and synthetic studies of estrogen-DNA adducts have relied on acidic conditions that artificially promote depurination, leaving stable N7-dG lesions poorly understood. To address this, we synthesized stable N7-dG catechol and estrone adducts using 2'-fluorinated deoxyguanosine, a modification that inhibits N-glycosidic bond cleavage. ROESY 2D NMR spectroscopy revealed through-space correlations consistent with a preferred anti-conformation in solution, supported by molecular modeling. Structural analysis suggests that these cationic aryl adducts likely preserve the Watson-Crick base pairing edge but may promote tautomerization capable of altering base pairing and generating G-to-A mutations. These findings provide the first synthesized stable models of N7-dG estrogen adducts and may support an alternative mechanism of estrogen-induced mutagenesis independent of depurination, enabling future biochemical investigations of related DNA repair and mutagenesis.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42197187 · DOI · PMC13209890
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies [5]
- Research article Steroid sulfatase: molecular biology, regulation, and inhibition [6]
- Research article The formation of estrogens by central neuroendocrine tissues [7]
- Research article The potential steroid hormone contribution of farm animals to freshwaters, the United Kingdom as a case study [8]
- Research article Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators [9]
- Research article Steroid hormones and endometrial cancer [10]
References
- Frederiksen H, Johannsen TH, Andersen SE, Albrethsen J, Landersoe SK, Petersen JH, et al.. Sex-specific Estrogen Levels and Reference Intervals from Infancy to Late Adulthood Determined by LC-MS/MS. . 2020. PMID 31720688 · DOI · PMC7007877
- Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, et al.. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. . 1998. PMID 9820189 · DOI · PMC2063014
- Yin X, Feng S, Chi Y, Liu J, Sun K, Guo C, et al.. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma. . 2018. PMID 29644882 · DOI · PMC6058671
- Baily PT, Lee S. Synthesis and Characterization of Chemically Stable N7-dG Estrone and Catechol Adducts. . 2026. PMID 42197187 · DOI · PMC13209890
- Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002. PMID 11959894 · DOI
- Reed MJ, Purohit A, Woo LW, Newman SP, Potter BV. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev. 2005. PMID 15561802 · DOI
- Naftolin F, Ryan KJ, Davies IJ, Reddy VV, Flores F, Petro Z, et al.. The formation of estrogens by central neuroendocrine tissues. Recent Prog Horm Res. 1975. PMID 812160 · DOI
- Johnson AC, Williams RJ, Matthiessen P. The potential steroid hormone contribution of farm animals to freshwaters, the United Kingdom as a case study. Sci Total Environ. 2006. PMID 16055169 · DOI
- Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol. 2003. PMID 14623518 · DOI
- Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res. 1978. PMID 359136
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.